Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia

Recruiting Observational Study
ALL, Childhood Pediatric Cancer Toxicity, Drug Adverse Drug Event Relapse Leukemia Drug Toxicity Drug Effect Drug Interaction
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 – 18
Sex
Any
Study type
Observational
Participants needed
556 (estimated)
Sponsor
University of Geneva, Switzerland · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). The project is an International multicenter setup. This collaborative research project between Switzerland and India includes one main center in Geneva that has conceptualized, design…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age \> 1 year old and ≤18 years old at enrolment * Previously untreated * ALL diagnosis confirmed by morphology and flow-cytometry * Indian origins * Fulfilling IciCle treatment protocol inclusion criteria and receiving treatment as per the protocol * Written Informed consent …
Contacts

Chakradhara Rao S Uppugudnuri

+41223794685

chakradhara.uppugunduri@unige.ch

CONTACT

Marc Ansari

+41223724731

Marc.Ansari@hcuge.ch

CONTACT